The value of LI-RADS ancillary features and biomarker for hepatocellular carcinoma ≤ 30 mm in Western and Eastern guidelines on extracellular agent and gadoxetic acid-enhanced MRI
European Radiology · 2026
DOI: 10.1007/s00330-026-12381-2 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Radiology, 2026. Verfasst von Jinhui Zhou und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Gadolinium DTPA, Magnetic Resonance Imaging. Die Arbeit nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China grant, Guangzhou Municipal Research Collaborative Innovation Projects, The 'Five Five' Project of the Third Affiliated Hospital of Sun Yat-sen University.
Abstract (Originalsprache)
OBJECTIVES: To evaluate the diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) v2018 ancillary features (AFs) and biomarker for hepatocellular carcinomas (HCCs) ≤ 30 mm in Western and Eastern guidelines. MATERIALS AND METHODS: This multicenter retrospective study included 1414 patients at risk for HCC who underwent MRI. The odds ratios of LI-RADS features and high alpha-fetoprotein (AFP) levels were assessed. Western and Eastern guidelines' diagnostic performances were compared via generalized estimating equations. RESULTS: A total of 1711 observations ≤ 30 mm were included in the extracellular contrast agent (ECA)-MRI training, internal/external ECA-MRI validation sets (n = 573, 245 and 212), internal EOB-MRI validation set (n = 681). Based on multivariable analysis, using combination of mild-moderate T2 hyperintensity and "either fat in mass or AFP ≥ 200 ng/mL," named "T2 + F/A" criterion, significantly improved the sensitivities of LR-5 v2018 (80.1-85.0% vs. 73.1-77.1%), EASL v2018 (78.4-84.3% vs. 72.2-75.7%), Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) v2022 (78.4-90.9% vs. 73.4-88.3%), Asian Pacific Association for the Study of the Liver (APASL) v2017 (81.5-94.8% vs. 73.7-90.9%) and Japan Society of Hepatology (JSH) v2021 (81.5-94.5% vs. 73.7-90.6%) for HCCs ≤ 30 mm in the training set and internal and external validation sets (all p < 0.05) without impairing specificity, except for that of Asian Pacific Association for the Study of the Liver (APASL) v2017 in the internal gadoxetic acid (EOB) validation set (75.5% vs. 77.2%, p = 0.044). CONCLUSION: Two LI-RADS AFs (mild-moderate T2 hyperintensity and fat in mass) and AFP ≥ 200 ng/mL are useful for improving the sensitivity of Western and Eastern guidelines for HCCs ≤ 30 mm. KEY POINTS: Question The sensitivities of Western and Eastern guidelines for hepatocellular carcinoma ≤ 30 mm are still insufficient on extracellular contrast agent-enhanced MRI and gadoxetic acid-enhanced MRI. Findings The use of the integrated "T2 + F/A" diagnostic criterion significantly improved the sensitivity of Western and Eastern guidelines for HCCs ≤ 30 mm on both ECA-MRI and EOB-MRI. Clinical relevance Addressing a critical gap in noninvasive small HCC diagnosis protocols in Western and Eastern guidelines across multiple MRI contrast agents. By enabling more accurate MRI diagnosis of HCCs ≤ 30 mm, our findings could increase patients receiving curative treatments at the early stage, potentially improving outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- Radiological Imaging Center, People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang, China.
- Department of Radiology, The Third Affiliated Hospital of Sun Yat-sen University Yuedong Hospital, Meizhou, China.
- Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Department of Radiology, Meizhou People's Hospital, Meizhou, China.
- Department of Radiology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Förderung
- National Natural Science Foundation of China grant
- Guangzhou Municipal Research Collaborative Innovation Projects
- The 'Five Five' Project of the Third Affiliated Hospital of Sun Yat-sen University
- Guangzhou Municipal Health Commission Clinical Speciality Technology
- Klarmaj City Science and Technology Program (Key R&D Program)
- Basic and Applied Basic Research Foundation of Guangdong Province
- Key Research and Development Program of Guangdong Province
- The ‘Five Five’ Project of the Third Affiliated Hospital of Sun Yat-sen University
Zitieren
APA
Zhou, J., Ouyang, S., Chen, H., Zhang, D., Wang, Y., Xiao, Y., Zeng, Y., Fang, Z., Wang, Y., Chen, L., Zhang, J., Zhang, T., Zhong, X., Yang, Q., Bu, X., Yang, Y., & Wang, J. (2026). The value of LI-RADS ancillary features and biomarker for hepatocellular carcinoma ≤ 30 mm in Western and Eastern guidelines on extracellular agent and gadoxetic acid-enhanced MRI. European Radiology. https://doi.org/10.1007/s00330-026-12381-2
Vancouver
Zhou J, Ouyang S, Chen H, Zhang D, Wang Y, Xiao Y, et al. The value of LI-RADS ancillary features and biomarker for hepatocellular carcinoma ≤ 30 mm in Western and Eastern guidelines on extracellular agent and gadoxetic acid-enhanced MRI. European Radiology. 2026. doi:10.1007/s00330-026-12381-2
BibTeX
@article{Zhou2026,
author = {Zhou, Jinhui and Ouyang, Siyu and Chen, Haimei and Zhang, Dingyue and Wang, Yan and Xiao, Yuanqiang and Zeng, Ying and Fang, Zebin and Wang, Yufeng and Chen, Lichun and Zhang, Jing and Zhang, Tianhui and Zhong, Xi and Yang, Qiqi and Bu, XinXin and Yang, Yang and Wang, Jin},
title = {The value of LI-RADS ancillary features and biomarker for hepatocellular carcinoma ≤ 30 mm in Western and Eastern guidelines on extracellular agent and gadoxetic acid-enhanced MRI},
journal = {European Radiology},
year = {2026},
doi = {10.1007/s00330-026-12381-2}
}
EUVIMED